These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 15483740

  • 1. Teveten (eprosartan) reduces future risk in hypertensive stroke patients.
    Cardiovasc J S Afr; 2004; 15(5):255-6. PubMed ID: 15483740
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Analysis of recent papers in hypertension. An angiotensin receptor blocker is more effective than a calcium channel blocker in secondary stroke prevention.
    Bloch MJ, Basile J.
    J Clin Hypertens (Greenwich); 2005 Aug; 7(8):489-92. PubMed ID: 16103761
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
    Larsen K, Hornnes N, Boysen G.
    Stroke; 2006 Jun; 37(6):1357; author reply 1358. PubMed ID: 16645128
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
    Rupp H.
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S25-9. PubMed ID: 18093411
    [Abstract] [Full Text] [Related]

  • 9. Effects of eprosartan on target organ protection.
    de la Sierra A.
    Vasc Health Risk Manag; 2006 Nov; 2(1):79-85. PubMed ID: 17319472
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Schwander B, Gradl B, Zöllner Y, Lindgren P, Diener HC, Lüders S, Schrader J, Villar FA, Greiner W, Jönsson B.
    Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
    [Abstract] [Full Text] [Related]

  • 13. Eprosartan: a review of its use in the management of hypertension.
    Robins GW, Scott LJ.
    Drugs; 2005 Sep; 65(16):2355-77. PubMed ID: 16266204
    [Abstract] [Full Text] [Related]

  • 14. Eprosartan (Teveten) offers new opportunities to prevent a second stroke.
    Cardiovasc J S Afr; 2005 Sep; 16(1):56. PubMed ID: 15778775
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Effect of eprosartan on psychophysiological functions of drivers with arterial hypertension].
    Tsfasman AZ, At'kova EO, Gutnikova OV.
    Kardiologiia; 2006 Sep; 46(10):18-20. PubMed ID: 17159852
    [Abstract] [Full Text] [Related]

  • 17. [Not all antihypertensive agents protect equally well].
    MMW Fortschr Med; 2006 Aug 17; 148(33-34):52. PubMed ID: 16981390
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients.
    Fogari R, Zoppi A, Ferrari I, Mugellini A, Preti P, Lazzari P, Derosa G.
    Horm Metab Res; 2009 Dec 17; 41(12):893-8. PubMed ID: 19708000
    [Abstract] [Full Text] [Related]

  • 20. Eprosartan: a review of its use in hypertension.
    Plosker GL.
    Drugs; 2009 Dec 17; 69(17):2477-99. PubMed ID: 19911859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.